22 May 2013
Keywords: merck, serono, sets, ph, iii, pd, drug
Article | 03 December 2007
Switzerland-based Merck Serono, a division of Germany's Merck KGaA, and
Italian partner Newron Pharmaceuticals have initiated a Phase III
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 December 2007
21 May 2013
© 2013 thepharmaletter.com